ABL Tyrosine Kinase Inhibitors Linked to Arterial Thrombosis – Blood Journals Portfolio
Blood Journals Portfolio shared a post on LinkedIn about a recent article by Richard Travers et al, published in Blood VTH:
”Another important study in observance of Deep Vein Thrombosis Awareness Month, focusing on Arterial Thrombosis.
‘Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis’ published on January 7, 2026, concluded that Dasatinib, ponatinib, and nilotinib damage ECs in different ways, all of which can contribute to arterial thrombosis.”
Title: Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis
Authors: Richard Travers, Alec Stepanian, Sebastiana Redford, Gregory Martin, Nicole L. Svedberg, Kun Xu, Glenn Merrill-Skoloff, Christopher Chen, Robert Flaumenhaft, Iris Z. Jaffe
Read the Full Article on Blood VTH
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 11:40Liz Devlin: When HHT Affects More Than What We Can See
-
Aug 14, 2026, 11:29Archil Jaliashvili: Can Italy Reduce Its Dependence on Imported Plasma
-
Aug 14, 2026, 11:21Osama Alabdi: Never Ignore a Weak Reaction in the Blood Bank
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children